Type: Human monoclonal anti-GM-CSF antibody
Status: GSK on May 6 disclosed plans for a Phase II multi-center, double-blind, randomized, placebo-controlled trial (NCT04376684) designed to assess the efficacy and safety of otilimab for the treatment of severe COVID-19-related pulmonary disease.
The study population, estimated at 800 participants, will consist of hospitalized participants with new onset hypoxia requiring significant oxygen support or requiring early invasive mechanical ventilation less than or equal to 48 hours before dosing. Participants will be randomized to receive a single intravenous (IV) infusion of otilimab or placebo, in addition to standard of care, GSK said. The trial’s estimated start date is May 18, and the estimated primary completion date is December 20.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data.
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types: